s of Naryx Pharma, Inc., a private pharmaceutical company. In 2004, Narachi left Amgen Inc., a leading therapeutics company, where he served as an officer and Vice President and, from 1999 through 2003, as General Manager of Amgen's Anemia Business. After joining Amgen in 1984, he held various positions throughout the organization including: Product Development Team Leader for NEUPOGEN®; Director of Clinical Operations in Thousand Oaks, CA
and Cambridge, UK
; Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development.
Mr. Narachi also currently serves as a member of the Board of Directors of BIO, the Biotechnology Industry Organization, and AMAG Pharmaceuticals, Inc., a publicly traded pharmaceutical company.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.
Contact: McDavid Stilwell , 858-875-8600
Page: 1 2 Related biology technology :1
|SOURCE Orexigen Therapeutics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Orexigen Therapeutics to Present at Upcoming Conferences2
. 2012-2013 Michael E. DeBakey Journalism Awards Call for Entries3
. Delta Point Strengthens Management and Expands Consultancy Services with Addition of Former AstraZeneca Executive Michael Hickey4
. Ariosa Diagnostics Welcomes New Board Member Michael A. Aicher5
. Michael Berman Joins InspireMD Board6
. Secretary of Department of Environmental Protection, Michael Krancer, to Facilitate Networking Session at Pittcon 20137
. IntelliCell BioSciences Announces Michael Hershman Joins the IntelliCell BioSciences Board of Directors8
. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release9
. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release10
. Sigma-Aldrich Elects Michael Marberry As Director11
. Dr. Michael Yaremchuk, Leading Performer of Custom-Designed Facial Implants, Pioneers Bespoke Plastic Surgery